| The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity J Barretina, G Caponigro, N Stransky, K Venkatesan, AA Margolin, S Kim, ... Nature 483 (7391), 603-607, 2012 | 8342 | 2012 |
| Recurrent BRAF mutations in Langerhans cell histiocytosis G Badalian-Very, JA Vergilio, BA Degar, LE MacConaill, B Brandner, ... Blood, The Journal of the American Society of Hematology 116 (11), 1919-1923, 2010 | 1316 | 2010 |
| Assessing the significance of chromosomal aberrations in cancer: methodology and application to glioma R Beroukhim, G Getz, L Nghiemphu, J Barretina, T Hsueh, D Linhart, ... Proceedings of the National Academy of Sciences 104 (50), 20007-20012, 2007 | 1264 | 2007 |
| High-throughput oncogene mutation profiling in human cancer RK Thomas, AC Baker, RM DeBiasi, W Winckler, T LaFramboise, WM Lin, ... Nature genetics 39 (3), 347-351, 2007 | 1176 | 2007 |
| Subtype-specific genomic alterations define new targets for soft-tissue sarcoma therapy J Barretina, BS Taylor, S Banerji, AH Ramos, M Lagos-Quintana, ... Nature genetics 42 (8), 715-721, 2010 | 818 | 2010 |
| MEK1 mutations confer resistance to MEK and B-RAF inhibition CM Emery, KG Vijayendran, MC Zipser, AM Sawyer, L Niu, JJ Kim, ... Proceedings of the National Academy of Sciences 106 (48), 20411-20416, 2009 | 799 | 2009 |
| Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway CA Lovejoy, W Li, S Reisenweber, S Thongthip, J Bruno, T De Lange, ... PLoS genetics 8 (7), e1002772, 2012 | 653 | 2012 |
| Mutations in the DDR2 Kinase Gene Identify a Novel Therapeutic Target in Squamous Cell Lung Cancer PS Hammerman, ML Sos, AH Ramos, C Xu, A Dutt, W Zhou, LE Brace, ... Cancer discovery 1 (1), 78-89, 2011 | 598 | 2011 |
| Drug-sensitive FGFR2 mutations in endometrial carcinoma A Dutt, HB Salvesen, TH Chen, AH Ramos, RC Onofrio, C Hatton, ... Proceedings of the National Academy of Sciences 105 (25), 8713-8717, 2008 | 425 | 2008 |
| Profiling critical cancer gene mutations in clinical tumor samples LE MacConaill, CD Campbell, SM Kehoe, AJ Bass, C Hatton, L Niu, ... PloS one 4 (11), e7887, 2009 | 372 | 2009 |
| A menin-MLL inhibitor induces specific chromatin changes and eradicates disease in models of MLL-rearranged leukemia AV Krivtsov, K Evans, JY Gadrey, BK Eschle, C Hatton, HJ Uckelmann, ... Cancer cell 36 (6), 660-673. e11, 2019 | 354 | 2019 |
| Therapeutic targeting of preleukemia cells in a mouse model of NPM1 mutant acute myeloid leukemia HJ Uckelmann, SM Kim, EM Wong, C Hatton, H Giovinazzo, JY Gadrey, ... Science 367 (6477), 586-590, 2020 | 219 | 2020 |
| EZH2 inhibitor efficacy in non-Hodgkin’s lymphoma does not require suppression of H3K27 monomethylation WD Bradley, S Arora, J Busby, S Balasubramanian, VS Gehling, ... Chemistry & biology 21 (11), 1463-1475, 2014 | 172 | 2014 |
| An alternative approach to ChIP-Seq normalization enables detection of genome-wide changes in histone H3 lysine 27 trimethylation upon EZH2 inhibition B Egan, CC Yuan, ML Craske, P Labhart, GD Guler, D Arnott, TM Maile, ... PloS one 11 (11), e0166438, 2016 | 162 | 2016 |
| Bromodomain inhibition of the transcriptional coactivators CBP/EP300 as a therapeutic strategy to target the IRF4 network in multiple myeloma AR Conery, RC Centore, A Neiss, PJ Keller, S Joshi, KL Spillane, ... Elife 5, e10483, 2016 | 131 | 2016 |
| MEN1 mutations mediate clinical resistance to menin inhibition F Perner, EM Stein, DV Wenge, S Singh, J Kim, A Apazidis, ... Nature 615 (7954), 913-919, 2023 | 122 | 2023 |
| The menin-MLL1 interaction is a molecular dependency in NUP98-rearranged AML EB Heikamp, JA Henrich, F Perner, EM Wong, C Hatton, Y Wen, ... Blood, The Journal of the American Society of Hematology 139 (6), 894-906, 2022 | 112 | 2022 |
| Pharmacological inhibition of the histone lysine demethylase KDM1A suppresses the growth of multiple acute myeloid leukemia subtypes JP McGrath, KE Williamson, S Balasubramanian, S Odate, S Arora, ... Cancer research 76 (7), 1975-1988, 2016 | 105 | 2016 |
| High-throughput mutation profiling of CTCL samples reveals KRAS and NRAS mutations sensitizing tumors toward inhibition of the RAS/RAF/MEK signaling cascade MK Kießling, PA Oberholzer, C Mondal, MB Karpova, MC Zipser, WM Lin, ... Blood, The Journal of the American Society of Hematology 117 (8), 2433-2440, 2011 | 105 | 2011 |
| Prospective enterprise-level molecular genotyping of a cohort of cancer patients LE MacConaill, E Garcia, P Shivdasani, M Ducar, R Adusumilli, ... The Journal of Molecular Diagnostics 16 (6), 660-672, 2014 | 93 | 2014 |